PoliticalRepoPoliticalRepo

Person

Official portrait of Rep. Bynum, Janelle S. [D-OR-5]

Rep. Bynum, Janelle S. [D-OR-5]

United States · Official source

Records

380 records where Rep. Bynum, Janelle S. [D-OR-5] is listed as a sponsor, author, or other actor. Search with topics and years

Bill· HRH.R. 9630 (119th)referred

BILL Drivers Act

United States · United States Congress · 9 July 2026

Bill· HRH.R. 9167 (119th)referred

Public Lands Integrity Act

United States · United States Congress · 4 June 2026

Public Lands Integrity Act This bill generally prohibits provisions that result in the sale, disposal, or transfer of federal lands from being included in reconciliation legislation by requiring the provisions to be considered extraneous under the Senate's Byrd Rule.  The Senate's Byrd Rule (named after it's principal author, Senator Robert Byrd of West Virginia) prohibits the inclusion of matter in reconciliation legislation that is extraneous to a congressional committee's reconciliation directives in the associated congressional budget resolution. Reconciliation is an expedited method by which Congress may adopt changes in spending and revenue laws to achieve the budgetary goals reflected in a congressional budget resolution. Reconciliation bills are considered by Congress using expedited legislative procedures that prevent a filibuster and restrict amendments in the Senate. For additional information, see CRS Report R48640, The Senate’s Byrd Rule: Frequently Asked Questions.

Bill· HRH.R. 8967 (119th)referred

Rural Community Hospital Demonstration Program Reauthorization

United States · United States Congress · 21 May 2026

Rural Community Hospital Demonstration Program Reauthorization This bill extends the Rural Community Hospital Demonstration Program for an additional five years. The program tests the feasibility of cost-based reimbursement under Medicare for small rural hospitals that are too large to qualify for special payment as critical access hospitals. The bill specifies that hospitals that participate in the program between December 30, 2024, and January 1, 2027, may continue to participate during the five-year extension period.

Resolution· HRESH.Res. 1252 (119th)passed

Resolution memorializing law enforcement officers killed in the line of duty.

United States · United States Congress · 4 May 2026

This resolution expresses support for police officers and other law enforcement personnel. The resolution further recognizes law enforcement officers across the United States in the pursuit of preserving safe and secure communities; the need to ensure that such officers have the equipment, training, and resources necessary to protect their health and safety while they are protecting the public; and the law enforcement community for acts of sacrifice and heroism. The resolution expresses condolences and appreciation to the loved ones of each law enforcement officer who has made the ultimate sacrifice in the line of duty.

Bill· HRH.R. 8592 (119th)referred

No WAR Act

United States · United States Congress · 30 April 2026

No War Appropriations through Reconciliation Act or the No WAR Act This bill establishes a budget point of order that prohibits considering reconciliation legislation that provides funding for unauthorized military force against Iran. (Reconciliation is an expedited method by which Congress may adopt changes in spending and revenue laws to achieve the budgetary goals reflected in a congressional budget resolution. Reconciliation bills are considered by Congress using expedited legislative procedures that prevent a filibuster and restrict amendments in the Senate.) Specifically, the point of order may be raised to prohibit the consideration of reconciliation legislation that provides budget authority for hostilities, including hostilities conducted by a proxy force, against Iran unless Congress has authorized such hostilities through a declaration of war or a specific authorization for use of military force. Under the bill, hostilities includes any offensive military operation, strike, covert action, or sustained engagement involving armed conflict against Iranian military forces, territory, or government institutions.  The point of order may be waived by a vote of at least three-fifths of all Senators duly chosen and sworn (60 votes if there are no vacancies).

Bill· HRH.R. 8503 (119th)referred

Save SNAP Act of 2026

United States · United States Congress · 27 April 2026

Bill· HRH.R. 8357 (119th)referred

6PPD Task Force Act

United States · United States Congress · 16 April 2026

Bill· HRH.R. 8261 (119th)referred

Chronic Care Management Improvement Act of 2026

United States · United States Congress · 14 April 2026

Chronic Care Management Improvement Act of 2026 This bill eliminates cost-sharing for chronic care management services under Medicare.

Bill· HRH.R. 8205 (119th)open

Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026

United States · United States Congress · 6 April 2026

Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 This bill reauthorizes through FY2031 and revises programs that support research and development of drugs and other therapies to address amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease) and other neurodegenerative diseases. The bill reauthorizes grants from the National Institutes of Health (NIH) for scientific research on investigational drugs to prevent or treat ALS for individuals not otherwise eligible for clinical trials, grants from the Food and Drug Administration (FDA) for research and development of therapies to prevent and treat ALS and other neurodegenerative diseases, and a Public-Private Partnership including the FDA and NIH that supports development and regulatory review of treatments for neurodegenerative diseases.  Also, the NIH, in considering renewal of its grants, must assess available information on the safety and efficacy of the investigational drugs. It must also require grantees to promptly report serious and unexpected adverse events associated with their investigational drugs. Additionally, the FDA must publish a plan describing actions it will take over a five-year period to foster development of safe and effective drugs, and facilitate access to investigational drugs, that treat ALS and other rare neurodegenerative diseases. The FDA must also publish a report describing the actions it has taken under the plan.

Bill· HRH.R. 8163 (119th)reported

Provider Reimbursement Stability Act of 2026

United States · United States Congress · 30 March 2026

Provider Reimbursement Stability Act of 2026 This bill allows for larger annual adjustments to the Medicare physician fee schedule. It also requires the Centers for Medicare & Medicaid Services (CMS) to make certain corrections to compensate for expenditures under the fee schedule that exceed a certain amount in a given year, and it limits how much certain adjustment factors may vary each year. Current law prohibits annual adjustments to the Medicare physician fee schedule that would result in a more than $20 million difference between the adjusted amount and the non-adjusted amount of total expenditures. The bill increases this threshold to $54.3 million beginning in 2027, with adjustments for inflation every five years beginning in 2032. Additionally, for certain services, the bill requires the CMS to determine the difference between expenditures based on estimated utilization of the service and expenditures based on actual utilization. If this difference exceeds a certain percentage of total expenditures under the fee schedule, the CMS must reconcile this difference by adjusting payments for the following year. This requirement applies to services for which payment was bundled with another service and there was a separate or add-on payment during the previous year. Finally, the CMS must update the prices and rates of each category of direct costs that affect payments (e.g., prices of equipment) at least every five years, with updates made to each category in the same year. The bill also prohibits the CMS from varying a certain adjustment factor by more than 2.5% each year.